- Home
- SRG vs ACIU Comparison
SRG vs ACIU Comparison
Compare SRG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ACIU
- Stock Information
- Founded
- SRG 2014
- ACIU 2003
- Country
- SRG United States
- ACIU Switzerland
- Employees
- SRG N/A
- ACIU N/A
- Industry
- SRG Real Estate Investment Trusts
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ACIU Health Care
- Exchange
- SRG Nasdaq
- ACIU Nasdaq
- Market Cap
- SRG 218.9M
- ACIU 247.4M
- IPO Year
- SRG 2015
- ACIU 2016
- Fundamental
- Price
- SRG $3.01
- ACIU $1.80
- Analyst Decision
- SRG
- ACIU Strong Buy
- Analyst Count
- SRG 0
- ACIU 2
- Target Price
- SRG N/A
- ACIU $12.00
- AVG Volume (30 Days)
- SRG 168.7K
- ACIU 190.8K
- Earning Date
- SRG 05-09-2025
- ACIU 03-13-2025
- Dividend Yield
- SRG N/A
- ACIU N/A
- EPS Growth
- SRG N/A
- ACIU N/A
- EPS
- SRG N/A
- ACIU N/A
- Revenue
- SRG $17,622,000.00
- ACIU $30,136,397.00
- Revenue This Year
- SRG N/A
- ACIU $120.91
- Revenue Next Year
- SRG N/A
- ACIU $13.82
- P/E Ratio
- SRG N/A
- ACIU N/A
- Revenue Growth
- SRG N/A
- ACIU 84.51
- 52 Week Low
- SRG $2.93
- ACIU $1.77
- 52 Week High
- SRG $9.87
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- SRG 38.22
- ACIU 21.61
- Support Level
- SRG $3.27
- ACIU $1.95
- Resistance Level
- SRG $3.40
- ACIU $2.05
- Average True Range (ATR)
- SRG 0.15
- ACIU 0.12
- MACD
- SRG -0.01
- ACIU -0.03
- Stochastic Oscillator
- SRG 29.21
- ACIU 0.00
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.